Apogee Therapeutics (NASDAQ:APGE) Reaches New 1-Year High – Time to Buy?

Posted by Geri Gentry on Aug 21st, 2026

Apogee Therapeutics Inc. (NASDAQ:APGE – Get Free Report) shares reached a new 52-week high on Wednesday . The company traded as high as $134.90 and last traded at $134.8220, with a volume of 44640 shares traded. The stock had previously closed at $134.57.

Analysts Set New Price Targets

APGE has been the topic of several recent analyst reports. Craig Hallum set a $135.11 price objective on shares of Apogee Therapeutics and gave the company a “hold” rating in a research report on Monday, June 22nd. Citigroup downgraded shares of Apogee Therapeutics from a “buy” rating to a “neutral” rating and upped their target price for the stock from $125.00 to $135.00 in a report on Tuesday, June 23rd. Truist Financial increased their price target on Apogee Therapeutics from $81.00 to $135.00 and gave the stock a “hold” rating in a research note on Thursday, August 13th. Rothschild & Co Redburn started coverage on Apogee Therapeutics in a report on Friday, May 1st. They set a “buy” rating and a $140.00 price target on the stock. Finally, Wedbush downgraded Apogee Therapeutics from an “outperform” rating to a “neutral” rating and set a $135.00 price objective on the stock. in a research report on Monday, June 22nd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $124.43.

Read Our Latest Stock Analysis on Apogee Therapeutics

Apogee Therapeutics Trading Up 0.0%

The firm has a market cap of $8.38 billion, a PE ratio of -31.05 and a beta of 0.34. The firm’s 50 day simple moving average is $128.38 and its 200 day simple moving average is $95.83.

Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.07). As a group, equities research analysts predict that Apogee Therapeutics Inc. will post -4.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 80,000 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $132.54, for a total transaction of $10,603,200.00. Following the completion of the transaction, the chief executive officer owned 1,015,987 shares in the company, valued at $134,658,916.98. This trade represents a 7.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Carl Dambkowski sold 26,400 shares of Apogee Therapeutics stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $132.60, for a total value of $3,500,640.00. Following the completion of the sale, the insider directly owned 179,248 shares in the company, valued at approximately $23,768,284.80. The trade was a 12.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 162,900 shares of company stock valued at $20,344,950. 24.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Apogee Therapeutics

Hedge funds have recently bought and sold shares of the business. Moore Capital Management LP bought a new position in Apogee Therapeutics during the second quarter valued at $2,655,000. Harvest Management LLC purchased a new stake in shares of Apogee Therapeutics during the 2nd quarter valued at about $10,486,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Apogee Therapeutics by 17.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 66,433 shares of the company’s stock valued at $8,818,000 after acquiring an additional 10,081 shares during the last quarter. Mint Tower Capital Management B.V. bought a new position in shares of Apogee Therapeutics in the 2nd quarter valued at about $2,186,000. Finally, Empowered Funds LLC purchased a new position in Apogee Therapeutics in the second quarter worth about $274,000. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Company Profile

(Get Free Report)

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.